Wan Tai Biology's (603392.SH) subsidiary has been shortlisted for the national immunization program's centralized vaccine procurement project.

Wisdom Finance APP News, Wantai Biopharmaceutical (603392.SH) announced that recently, the company's wholly-owned subsidiary Xiamen Wantai Canghai Biotechnology Co., Ltd. participated in the bidding work for the centralized procurement project of the national Immunization Program for 2025 - the purchase project of bivalent human papillomavirus vaccine. The company's bivalent human papillomavirus vaccine (E. coli) was shortlisted.